Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Extrapyramidal side effects and
increased serum prolactin following fluoxetine, a new
antidepressant.
Meltzer HY, Young M, Metz J, Fang
VS, Schyve PM, Arora RC.
Fluoxetine (Lilly 110140) is a
potent, specific serotonin (5-HT) uptake blocker which is being tested
in man for antidepressant activity. One of 9 depressed patients
receiving this drug developed a dystonic reaction, parkinsonian
rigidity, and increased serum prolactin levels, all signs of decreased
dopaminergic activity. Homovanillic acid levels also decreased in the
cerebrospinal fluid of this subject. We postulate that fluoxetine, via
the increase in 5-HT activity resulting from 5-HT uptake blockade,
inhibited both the nigro-striatal and tubero-infundibular dopaminergic
neurons. These results provide additional evidence for a linkage between
serotonergic and dopaminergic neurons in man.
Publication Types:
PMID: 313977 [PubMed - indexed for
MEDLINE]
|